{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:09:51Z","timestamp":1791079791136,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006153","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T00:00:00Z","timestamp":1232496000000}}],"reference-count":136,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006153.pub2","type":"journal-article","created":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T17:17:45Z","timestamp":1233681465000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment for familial amyotrophic lateral sclerosis\/motor neuron disease"],"prefix":"10.1002","author":[{"given":"Michael","family":"Benatar","sequence":"first","affiliation":[{"name":"University of Miami; Department of Neurology; 1120 NW 14th Street Clinical Research Building, Suite 1318 Miami Florida USA 33136"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Kurent","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina; Department of Neurosciences and Medicine; 135 Rutledge Avenue Room 1237, PO Vox 250591 Charleston USA SC 29425-0591"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan H","family":"Moore","sequence":"additional","affiliation":[{"name":"California Pacific Medical Center; Research Institute; 475 Brannan St Suite 220 San Francisco CA USA 94107"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.61.4.456","article-title":"A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis [see comment]","volume":"61","author":"Cudkowicz","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.20903","article-title":"Trial of celecoxib in amyotrophic lateral sclerosis","volume":"60","author":"Cudkowicz","year":"2006","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mus.21059","article-title":"Arimoclomol at dosages up to 300mg\/day is well tolerated and safe in amyotropic lateral sclerosis","volume":"38","author":"Cudkowicz","year":"2008","journal-title":"Muscle and Nerve"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"A randomized sequential trial of creatine in amyotrophic lateral sclerosis","volume":"53","author":"Groeneveld","year":"2003","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD006153.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"A clinical trial of creatine in ALS","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archneur.1988.00520280027011","article-title":"A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis","volume":"45","author":"Appel","year":"1988","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jnnp.56.2.197","article-title":"A pilot trial of dextromethorphan in amyotrophic lateral sclerosis","volume":"56","author":"Askmark","year":"1993","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"12","key":"10.1002\/14651858.CD006153.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1212\/WNL.43.12.2466","article-title":"Branched-chain amino acids and amyotrophic lateral sclerosis: a treatment failure? The Italian Study Group","volume":"43","year":"1993","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1212\/WNL.54.2.469","article-title":"A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group","volume":"54","author":"Beghi","year":"2000","journal-title":"Neurology"},{"issue":"23","key":"10.1002\/14651858.CD006153.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/01.wnl.0000264418.92308.a4","article-title":"A randomized controlled trial of resistance exercise in individuals with ALS","volume":"68","author":"Bello-Haas","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD006153.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group","volume":"330","author":"Bensimon","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis.[see comment]","volume":"249","author":"Bensimon","year":"2002","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006153.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1600-0404.2007.00643.x","article-title":"Acute action of aminophylline in patients with amyotrophic lateral sclerosis","volume":"115","author":"Berto","year":"2007","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00862977","article-title":"A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis","volume":"239","author":"Blin","year":"1992","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00002826-199619020-00009","article-title":"A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis","volume":"19","author":"Blin","year":"1996","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1212\/WNL.51.2.583","article-title":"A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS\/IGF-I Study Group","volume":"51","author":"Borasio","year":"1998","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(05)70326-4","article-title":"Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial [see comment]","volume":"5","author":"Bourke","year":"2006","journal-title":"Lancet Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006153.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/WNL.34.8.1079","article-title":"A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis","volume":"34","author":"Bradley","year":"1984","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archneur.1974.00490340050011","article-title":"Inosiplex and amyotrophic lateral sclerosis. Therapeutic trial in patients on Guam","volume":"30","author":"Brody","year":"1974","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1212\/WNL.36.2.146","article-title":"Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis","volume":"36","author":"Brooke","year":"1986","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0021|cit21","first-page":"264","article-title":"Intravenous (10 mg\/kg) thyrotropin releasing hormone (TRH) administration in amyotrophic lateral sclerosis (ALS): decreased loss of muscle strength in TRH-treated patients during parallel-placebo controlled pilot study","volume":"232","author":"Brooks","year":"1985","journal-title":"Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1212\/WNL.46.5.1244","article-title":"A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group","volume":"46","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.36.2.141","article-title":"A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis","volume":"36","author":"Caroscio","year":"1986","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/BF02341783","article-title":"Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial","volume":"19","author":"Chi\u00f2","year":"1998","journal-title":"Italian Journal of Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/146608201300079364","article-title":"A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group","volume":"2","author":"Desnuelle","year":"2001","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/ana.410350205","article-title":"Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation [see comment]","volume":"35","author":"Drachman","year":"1994","journal-title":"Annals of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006153.pub2-BIB0027|cit27","first-page":"S125","article-title":"The value of muscle exercise in patients with amyotrophic lateral sclerosis","volume":"187","author":"Drory","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1017\/S0317167100048204","article-title":"Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine","volume":"20","author":"Eisen","year":"1993","journal-title":"Canadian Journal of Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0029|cit29","article-title":"High-dose alpha-interferon treatment in amyotrophic lateral sclerosis","volume":"13","author":"F\u00e4rkkil\u00e4","year":"1996","journal-title":"Biotechnologia Aplicada"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1073\/pnas.0708022105","article-title":"Lithium delays progression of amyotrophic lateral sclerosis.[see comment][erratum appears in Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16404-7]","volume":"105","author":"Fornai","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/jnnp.58.2.201","article-title":"Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368)","volume":"58","author":"Goonetilleke","year":"1995","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/01.wnl.0000204235.81272.e2","article-title":"Randomized controlled phase II trial of glatiramer acetate in ALS","volume":"66","author":"Gordon","year":"2006","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD006153.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(07)70270-3","article-title":"Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.[see comment]","volume":"6","author":"Gordon","year":"2007","journal-title":"Lancet Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/17482960802195632","article-title":"A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS","volume":"9","author":"Gordon","year":"2008","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00702-004-0220-1","article-title":"High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study","volume":"112","author":"Graf","year":"2005","journal-title":"Journal of Neural Transmission"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.1997.tb00231.x","article-title":"A clinical trial of dextromethorphan in amyotrophic lateral sclerosis","volume":"96","author":"Gredal","year":"1997","journal-title":"Acta Neurologica Scandinavica"},{"issue":"10","key":"10.1002\/14651858.CD006153.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1136\/jnnp.50.10.1359","article-title":"Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease","volume":"50","author":"Guiloff","year":"1987","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD006153.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1212\/WNL.34.8.1083","article-title":"Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial","volume":"34","author":"Harrington","year":"1984","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0960-8966(93)90025-F","article-title":"Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease","volume":"3","author":"Hesselmans","year":"1993","journal-title":"Neuromuscular Disorders"},{"issue":"12","key":"10.1002\/14651858.CD006153.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/jnnp.47.12.1332","article-title":"Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone","volume":"47","author":"Imoto","year":"1984","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0041|cit41","first-page":"S25","article-title":"A randomised trial of antioxidative therapy in amyotrophic lateral sclerosis","volume":"243","author":"Janik","year":"1996","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0042|cit42","first-page":"237","article-title":"Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis","volume":"41","author":"Jossan","year":"1994","journal-title":"Journal of Neural Transmission Supplementum"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/WNL.52.7.1427","article-title":"A controlled trial of recombinant methionyl human BDNF in ALS. The BDNF Study Group (Phase III)","volume":"52","year":"1999","journal-title":"Neurology"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD006153.pub2-BIB0044|cit44","first-page":"A238, Abstract","article-title":"Is a phase III trial of coenzyme Q10 (CoQ10) for ALS justified? Results of a phase II randomized controlled trial of CoQ10 for ALS","volume":"70","author":"Kaufmann","year":"2008","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006153.pub2-BIB0045|cit45","first-page":"A255","article-title":"Double-blind controlled crossover trial of ultra-high dose methylcobalamin for amyotrophic lateral sclerosis","volume":"54","author":"Kodama","year":"2000","journal-title":"Neurology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD006153.pub2-BIB0046|cit46","first-page":"101","article-title":"[The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trial]","volume":"35","author":"Kwieci\u0144ski","year":"2001","journal-title":"Neurologia i Neurochirurgia Polska"},{"issue":"9013","key":"10.1002\/14651858.CD006153.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"issue":"6 Suppl 4","key":"10.1002\/14651858.CD006153.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1212\/WNL.47.6_Suppl_4.242S","article-title":"A confirmatory dose-ranging study of riluzole in ALS. ALS\/Riluzole Study Group-II","volume":"47","author":"Lacomblez","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14660820410018973","article-title":"Xaliproden in amyotrophic lateral sclerosis: early clinical trials","volume":"5","author":"Lacomblez","year":"2004","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.49.6.1621","article-title":"Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS\/IGF-I Study Group","volume":"49","author":"Lai","year":"1997","journal-title":"Neurology"},{"issue":"4 Suppl 2","key":"10.1002\/14651858.CD006153.pub2-BIB0051|cit51","first-page":"S94","article-title":"Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS\/IGF-I Study Group","volume":"47","author":"Lange","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/archneur.55.1.93","article-title":"Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis","volume":"55","author":"Lange","year":"1998","journal-title":"Archives of Neurology"},{"issue":"5-6","key":"10.1002\/14651858.CD006153.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/17482960902995246","article-title":"Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability","volume":"10","author":"Lauria","year":"2009","journal-title":"Amyotrophic lateral sclerosis: official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD006153.pub2-BIB0054|cit54","first-page":"S63, Abstract n","article-title":"Double-blind, placebo controlled safety study of ritonavir and hydroxyurea in patients with ALS","volume":"62","author":"Lomen-Hoerth","year":"2007","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archneur.1995.00540300031009","article-title":"Randomized double-blind controlled trial of acetylcysteine in amyotrophic lateral sclerosis","volume":"52","author":"Louwerse","year":"1995","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00863772","article-title":"An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis","volume":"241","author":"Mazzini","year":"1994","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/01.wnl.0000191326.40772.62","article-title":"Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial","volume":"66","author":"Meininger","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00415-008-0756-3","article-title":"Thalidomide causes sinus bradycardia in ALS","volume":"255","author":"Meyer","year":"2008","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0060|cit60","first-page":"330","article-title":"Controlled trial of nimodipine in amyotrophic lateral sclerosis","volume":"36","author":"Miller","year":"1994","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.47.6.1383","article-title":"Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group","volume":"47","author":"Miller","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ana.410390215","article-title":"A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group","volume":"39","author":"Miller","year":"1996","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1212\/WNL.56.7.843","article-title":"Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis","volume":"56","author":"Miller","year":"2001","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006153.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1212\/01.wnl.0000269676.07319.09","article-title":"Phase II\/III randomized trial of TCH346 in patients with ALS","volume":"69","author":"Miller","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.36.2.152","article-title":"Amyotrophic lateral sclerosis: effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials","volume":"36","author":"Mitsumoto","year":"1986","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1212\/WNL.42.5.1049","article-title":"Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system","volume":"42","author":"Munsat","year":"1992","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0067|cit67","first-page":"335","article-title":"A double blind placebo controlled study of myotrophin (CEP 151) in the treatment of amyotrophic lateral sclerosis","volume":"38","author":"Murphy","year":"1995","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1179\/016164105X39860","article-title":"Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis","volume":"27","author":"Nagano","year":"2005","journal-title":"Neurological Research"},{"issue":"1-2","key":"10.1002\/14651858.CD006153.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/17482960902933809","article-title":"Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: A pilot study","volume":"11","author":"Nefussy","year":"2010","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"8","key":"10.1002\/14651858.CD006153.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1212\/WNL.24.8.721","article-title":"The administration of guanidine in amyotrophic lateral sclerosis","volume":"24","author":"Norris","year":"1974","journal-title":"Neurology"},{"issue":"9","key":"10.1002\/14651858.CD006153.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1212\/WNL.36.9.1263","article-title":"Trial of octacosanol in amyotrophic lateral sclerosis","volume":"36","author":"Norris","year":"1986","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/clpt.1993.206","article-title":"Trial of oral physostigmine in amyotrophic lateral sclerosis","volume":"54","author":"Norris","year":"1993","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006153.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14660820050515197","article-title":"A phase I\/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis [see comment]","volume":"1","author":"Ochs","year":"2000","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410050413","article-title":"Transfer factor is ineffective in amyotrophic lateral sclerosis","volume":"5","author":"Olarte","year":"1979","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1212\/WNL.35.7.1063","article-title":"Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis","volume":"35","author":"Olarte","year":"1985","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD006153.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1212\/WNL.28.12.1293","article-title":"Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study","volume":"28","author":"Olson","year":"1978","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1529-8027.2000.00513-45.x","article-title":"An open study of riluzole versus riluzole plus gabapentin in amyotrophic lateral sclerosis","volume":"5","author":"Palma","year":"2000","journal-title":"Journal of the Peripheral Nervous System"},{"issue":"3","key":"10.1002\/14651858.CD006153.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3109\/17482960903307805","article-title":"A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis","volume":"11","author":"Pascuzzi","year":"2010","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD006153.pub2-BIB0079|cit79","first-page":"A192","article-title":"A randomized, placebo-controlled, sequential trial of valproic acid in ALS","volume":"70","author":"Piepers","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.21620","article-title":"Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis","volume":"66","author":"Piepers","year":"2009","journal-title":"Annals of Neurology"},{"issue":"8593","key":"10.1002\/14651858.CD006153.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(88)91841-7","article-title":"Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis","volume":"1","author":"Plaitakis","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10072-005-0474-x","article-title":"Minocycline in amyotrophic lateral sclerosis: a pilot study","volume":"26","author":"Pontieri","year":"2005","journal-title":"Neurological Sciences"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archneur.1980.00500530039003","article-title":"Modified snake venom in amyotrophic lateral sclerosis - lack of clinical effectiveness","volume":"37","author":"Rivera","year":"1980","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/17482960802028890","article-title":"Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS","volume":"9","author":"Rosenfeld","year":"2008","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0404.2003.00111.x","article-title":"A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters","volume":"108","author":"Ryberg","year":"2003","journal-title":"Acta Neurologica Scandinavica"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1212\/01.WNL.0000156913.24701.72","article-title":"A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS","volume":"64","author":"Scelsa","year":"2005","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/mus.880160608","article-title":"Recombinant growth hormone treatment of amyotrophic lateral sclerosis","volume":"16","author":"Smith","year":"1993","journal-title":"Muscle and Nerve"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0022-510X(94)90188-0","article-title":"Treatment of ALS with high dose pulse cyclophosphamide","volume":"124 Suppl","author":"Smith","year":"1994","journal-title":"Journal of the Neurological Sciences"},{"issue":"22","key":"10.1002\/14651858.CD006153.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1212\/01.wnl.0000335970.78664.36","article-title":"Subcutaneous IGF-1 is not beneficial in 2-year ALS trial","volume":"71","author":"Sorenson","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/17482960701547875","article-title":"Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis","volume":"8","author":"Steele","year":"2007","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"5-6","key":"10.1002\/14651858.CD006153.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3109\/17482960802709416","article-title":"Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial","volume":"10","author":"Stommel","year":"2009","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0092|cit92","first-page":"821","article-title":"[Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes]","volume":"32","author":"Szczudlik","year":"1998","journal-title":"Neurologia i Neurochirurgia Polska"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/WNL.47.5.1220","article-title":"A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data","volume":"47","author":"Tandan","year":"1996","journal-title":"Neurology"},{"issue":"8","key":"10.1002\/14651858.CD006153.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF00328503","article-title":"Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis","volume":"236","author":"Testa","year":"1989","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0303-8467(92)90110-O","article-title":"Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study","volume":"94","author":"Testa","year":"1992","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/WNL.29.1.77","article-title":"Double-blind study of modified neurotoxin in motor neuron disease","volume":"29","author":"Tyler","year":"1979","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0097|cit97","first-page":"851","article-title":"Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan","volume":"182","author":"Yanagisawa","year":"1997","journal-title":"Igakuno Ayumi"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00002826-199410000-00004","article-title":"Can nimodipine affect progression of motor neuron disease? A double-blind pilot study","volume":"17","author":"Ziv","year":"1994","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1474-4422(10)70068-5","article-title":"Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Aggarwal","year":"2010","journal-title":"Lancet Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17482960802320487","article-title":"Phase 2 study of sodium phenylbutyrate in ALS","volume":"10","author":"Cudkowicz","year":"2009","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neulet.2009.08.020","article-title":"Motor cortex stimulation for ALS: a double blind placebo-controlled study","volume":"464","author":"Lazzaro","year":"2009","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21743","article-title":"Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III","volume":"66","author":"Kaufmann","year":"2009","journal-title":"Annals of Neurology"},{"issue":"5-6","key":"10.1002\/14651858.CD006153.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3109\/17482960902803432","article-title":"Glatiramer acetate has no impact on disease progression in ALS at 40 mg\/day: a double- blind, randomized, multicentre, placebo-controlled trial","volume":"10","author":"Meininger","year":"2009","journal-title":"Amyotrophic Lateral Sclerosis"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/WNF.0b013e3181c47569","article-title":"Safety, tolerability, and cerebrospinal fluid penetration of ursodeoxycholic acid in patients with amyotrophic lateral sclerosis","volume":"33","author":"Parry","year":"2010","journal-title":"Clinical Neuropharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006153.pub2-BIB0105|cit105","first-page":"A36, Abstract n","article-title":"A double-blind, placebo-controlled, randomized trial of growth hormone as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: preliminary MRS, hormonal, and population analysis","volume":"72","author":"Sacca","year":"2009","journal-title":"Neurology"},{"issue":"1-2","key":"10.1002\/14651858.CD006153.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2008.01.011","article-title":"The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis","volume":"270","author":"Zanette","year":"2008","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0107|cit107","unstructured":"Benatar M Cudkowicz M Phase II\/III Randomized, Placebo-controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00706147?term=arimoclomol&rank=1"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1212\/WNL.52.7.1427","article-title":"A controlled trial of recombinant methionyl human BDNF in ALS","volume":"52","author":"The BDNF Study Group (Phase III)","year":"1999","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1212\/WNL.54.2.469","article-title":"A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group","volume":"54","author":"Beghi","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0110|cit110","doi-asserted-by":"crossref","unstructured":"Benatar M Polak M Kaplan S Glass J Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? Journal of the Neurological Sciences 2006 3 9","DOI":"10.1016\/j.jns.2006.05.069"},{"issue":"9","key":"10.1002\/14651858.CD006153.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJM199403033300901","article-title":"A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole study group","volume":"330","author":"Bensimon","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s004150200071","article-title":"A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis","volume":"249","author":"Bensimon","year":"2002","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1212\/WNL.51.2.583","article-title":"A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS\/IGF-I Study Group","volume":"51","author":"Borasio","year":"1998","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1212\/01.wnl.0000299187.90432.3f","article-title":"Prevalence of SOD1 mutations in the Italian ALS population","volume":"70","author":"Chi\u00f2","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1212\/WNL.46.5.1244","article-title":"A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group","volume":"46","year":"1996","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/ana.410410212","article-title":"Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis","volume":"41","author":"Cudkowicz","year":"1997","journal-title":"Annals of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1212\/WNL.61.4.456","article-title":"A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis","volume":"61","author":"Cudkowicz","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/146608201300079364","article-title":"A double-blind, placebo-controlled randomized clinical trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group","volume":"2","author":"Desnuelle","year":"2001","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0404.1983.tb04810.x","article-title":"Epidemiology of motor neuron disease in northern Sweden","volume":"68","author":"Forsgren","year":"1983","journal-title":"Acta Neurologica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD006153.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.10554","article-title":"A randomized sequential trial of creatine in amyotrophic lateral sclerosis","volume":"53","author":"Groeneveld","year":"2003","journal-title":"Annals of Neurology"},{"issue":"5166","key":"10.1002\/14651858.CD006153.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.8209258","article-title":"Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation","volume":"264","author":"Gurney","year":"1994","journal-title":"Science"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0122|cit122","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0123|cit123","unstructured":"Miller T Cudkowicz M Safety, Tolerability, and Activity Study of ISIS SOD Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations (SOD-1) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01041222?term=isis&rank=8"},{"issue":"5918","key":"10.1002\/14651858.CD006153.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1126\/science.1166066","article-title":"Mutations in the FUS\/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis","volume":"323","author":"Kwiatkowski","year":"2009","journal-title":"Science"},{"issue":"9013","key":"10.1002\/14651858.CD006153.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","article-title":"Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis\/Riluzole Study Group II","volume":"347","author":"Lacomblez","year":"1996","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD006153.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.49.6.1621","article-title":"Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS\/IGF-I Study Group","volume":"49","author":"Lai","year":"1997","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.1988.tb06965.x","article-title":"Motor neuron disease in Cantabria","volume":"77","author":"L\u00f3pez-Vega","year":"1988","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14660820410019602","article-title":"Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials","volume":"5","author":"Meininger","year":"2004","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"7","key":"10.1002\/14651858.CD006153.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1212\/WNL.56.7.843","article-title":"Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis","volume":"56","author":"Miller","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD006153.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0022-510X(93)90245-T","article-title":"Onset, natural history and outcome in idiopathic adult motor neuron disease","volume":"118","author":"Norris","year":"1993","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1002\/14651858.CD006153.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1212\/WNL.48.3.746","article-title":"Clinical and functional investigation of 10 missense mutations and a novel frameshift insertion mutation of the gene for copper-zinc superoxide dismutase in UK families with amyotrophic lateral sclerosis","volume":"48","author":"Orrell","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006153.pub2-BIB0132|cit132","unstructured":"Lange D SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01083667?term=lange+d&rank=5"},{"issue":"9","key":"10.1002\/14651858.CD006153.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1212\/01.WNL.0000142992.81995.F0","article-title":"A clinical trial of creatine in ALS","volume":"63","author":"Shefner","year":"2004","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD006153.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1212\/01.wnl.0000296811.19811.db","article-title":"Genetics of familial amyotrophic lateral sclerosis","volume":"70","author":"Valdmanis","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006153.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1474-4422(08)70071-1","article-title":"TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis","volume":"7","author":"Deerlin","year":"2008","journal-title":"Lancet Neurology"},{"issue":"5918","key":"10.1002\/14651858.CD006153.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.1165942","article-title":"Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6","volume":"323","author":"Vance","year":"2009","journal-title":"Science"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD006153.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:55:45Z","timestamp":1628546145000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006153.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":136,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006153.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}